This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
29 Oct 2014

Next Generation of CO2 Incubators for Demanding Cell Culture Applications

Cell culture scientists working with sensitive cultures such as stem and primary cells, can turn to a new CO2 incubator that combines the latest technologies for optimal cell growth and contamination control designed to create uniform growth conditions with consistency and reliability.

 

The Thermo Scientific Heracell VIOS incubator series is ideal for academic research and pharmaceutical applications, allowing scientists to maximize their productivity with excellent reproducibility, reliability and efficiency.

 

“Reproducibility and contamination prevention are critical when it comes to sensitive cultures to ensure the integrity of your research,” said Doug Wernerspach, Global Business Director, Thermo Fisher Scientific. “Our new Heracell VIOS series leverage our long history of CO2 technology leadership with innovations, including our new THRIVE active airflow and proven decontamination that are critical for today’s demanding cell culture applications.”

 

Incorporating the breakthrough THRIVE active airflow technology, the Heracell VIOS delivers a homogeneous culturing environment with fast recovery for unwanted variation. Designed to protect valuable cultures from contamination, the Heracell VIOS is equipped with

• ISO class 5 HEPA filters to protect against airborne microbes and particulates
• Steri-Run, a fully automatic on-demand overnight 180 °C sterilisation cycle assures uniform 6-log high-temperature sterilisation on all surfaces
• Condensation-free chamber with covered, protected humidity reservoir
• 100% pure copper interiors to provide lasting sustainability and easy maintenance.


For operation simplicity, the intelligent iCAN touchscreen interface provides complete data visibility to monitor all incubator interaction, featuring on-screen menu prompts, error and usage monitoring, downloadable data logging with a standard USB, performance trend graphing and multiple language selection, including English, Spanish, German, French, Italian, Japanese and Mandarin.

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.